Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC

Zai Lab Ltd

LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.
TTFields + immune checkpoint inhibitors demonstrated significant OS benefit; positive trend with TTFields + docetaxel.
Zai Lab has exclusive license to develop and commercialize TTFields in mainland China, Hong Kong, Macau, and Taiwan.
Novocure plans to file PMA with FDA and CE Mark in EU in H2 2023; full results at future medical congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.